share_log

微創醫療：(重新刊發以供債券持有人參考) 截至二零二三年十二月三十一日止年度之全年業績預告

MICROPORT: (Re-published for debt holders information) ESTIMATED ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 8 04:05
Summary by Moomoo AI
微創醫疗科學有限公司於2024年3月5日發布截至2023年12月31日止年度全年業績預告。儘管面臨國內外不利因素，集團銷售收入同比增長超過15%，主要得益於附屬公司新產品推廣及市場份額提升。其中，心脈醫療、微創腦科學、心通醫療及微創機器人均實現顯著收入增長。集團其他主要業務亦實現穩定增長，新興業務收入錄得指數級增長。預計年度虧損不超過580.0百萬美元，較去年同期減少，剔除一次性及非現金性撥備及損失後，年度虧損不超過436.0百萬美元，同比減虧超過13%。公司將繼續聚焦業務，提高收入，降低相關費用，致力於未來幾年大幅減虧並實現盈虧平衡。本公司股份及證券持有人及潛在投資者應審慎行事，並留意於3月末前刊發的年度業績公告。
微創醫疗科學有限公司於2024年3月5日發布截至2023年12月31日止年度全年業績預告。儘管面臨國內外不利因素，集團銷售收入同比增長超過15%，主要得益於附屬公司新產品推廣及市場份額提升。其中，心脈醫療、微創腦科學、心通醫療及微創機器人均實現顯著收入增長。集團其他主要業務亦實現穩定增長，新興業務收入錄得指數級增長。預計年度虧損不超過580.0百萬美元，較去年同期減少，剔除一次性及非現金性撥備及損失後，年度虧損不超過436.0百萬美元，同比減虧超過13%。公司將繼續聚焦業務，提高收入，降低相關費用，致力於未來幾年大幅減虧並實現盈虧平衡。本公司股份及證券持有人及潛在投資者應審慎行事，並留意於3月末前刊發的年度業績公告。
MICROCHUN MEDICAL SCIENCES CO., LTD. ISSUED ON MARCH 5, 2024 ITS ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023. Despite the domestic and foreign adverse factors, the Group's sales revenue grew by more than 15% year-on-year, mainly driven by new product promotion and increased market share by subsidiaries. Among them, Cardiac Medicine, Micro Brain Science, Cardiac Medicine and Micro-Startup Robotics all achieved significant revenue growth. The Group's other major businesses also achieved steady growth, with income from emerging businesses recording index level growth. The annual loss is expected to be no more than $580.0 million, a decrease from the same period last year. Excluding one-time and non-cash provisions and losses, the annual loss will not exceed $436.0 million...Show More
MICROCHUN MEDICAL SCIENCES CO., LTD. ISSUED ON MARCH 5, 2024 ITS ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023. Despite the domestic and foreign adverse factors, the Group's sales revenue grew by more than 15% year-on-year, mainly driven by new product promotion and increased market share by subsidiaries. Among them, Cardiac Medicine, Micro Brain Science, Cardiac Medicine and Micro-Startup Robotics all achieved significant revenue growth. The Group's other major businesses also achieved steady growth, with income from emerging businesses recording index level growth. The annual loss is expected to be no more than $580.0 million, a decrease from the same period last year. Excluding one-time and non-cash provisions and losses, the annual loss will not exceed $436.0 million, a year-over-year loss of more than 13%. The Company will continue to focus on the business, increase revenue, reduce related expenses, and strive to significantly reduce losses and achieve a balance of profit and loss in the coming years. Holders of shares and securities of the Company and potential investors should exercise caution and pay attention to the annual results announcement published before the end of March.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more